NDEI will provide samples for Genizon’s genotyping study.

Genizon BioSciences and Neuropsychiatrie, Decouverte & Innovation (NDEI) will work together to enhance discoveries made by Genizon earlier this year in a genome wide association study of schizophrenia.

Genizon’s previous work identified multiple genes associated with the disease using DNA samples from patients in the Quebec Founder Population. The population which, because of its high level of genetic homogeneity, is considered among the best for disease gene discovery, according to the companies.

Under the terms of the agreement, NDEI will be supplying a second set of samples collected from the Quebec Founder Population. Genotyping of these samples and statistical analyses of the data will be conducted at Genizon’s St. Laurent, Quebec, research center.

Previous articleScientists Identify 57 Genomic Regions Associated with Lung Cancer
Next articleDSM Pharmaceuticals Incorporates Formulation Development and CTM Manufacturing into Services